N.I.S of AIT in Adult Patients With House Dust Mite Allergy in Real Practice in France

Inclusion Criteria: * At the discretion of the investigator, patient who will be prescribed ACARIZAX® in line with the approved Summary of Product Characteristics (SmPC) and who have been informed, after explicit written explanation and willing to participate in the study by signed consent Exclusion Criteria: * Patient who did not have 12 months prior inclusion or have an on-going, House Dust Mite (HDM) Allergy Immunotherapy (AIT).